EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Abbott Laboratories (Pakistan) EBITDA Margin % Related Terms
Abbott Laboratories (Pakistan) EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:ABOT vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Abbott Laboratories (Pakistan)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories (Pakistan) EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Abbott Laboratories (Pakistan)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories (Pakistan)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (Pakistan) (KAR:ABOT) has a EBITDA Margin % of 21.45% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Abbott Laboratories (Pakistan) and its competitors. This is 14% above median its historical median of 18.81. Over the past decade, Abbott Laboratories (Pakistan)'s EBITDA Margin % has ranged from 7.56 to 26.20. According to the industry distribution chart, Abbott Laboratories (Pakistan) ranks #283 out of 955 companies in the Drug Manufacturers industry, placing it in the top 29.6%.
Is Abbott Laboratories (Pakistan)'s EBITDA Margin % too high?
Abbott Laboratories (Pakistan)'s current EBITDA Margin % of 21.45% is 14% above median its 10-year median of 18.81. Over the past 10 years, this metric has ranged from a low of 7.56 to a high of 26.20. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Abbott Laboratories (Pakistan)'s value of 21.45% is 72.4% above this industry median. Based on the distribution chart, Abbott Laboratories (Pakistan) ranks #283 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Abbott Laboratories (Pakistan) has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories (Pakistan)'s EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Abbott Laboratories (Pakistan) ranks #283 out of 955 companies for EBITDA Margin %. This puts Abbott Laboratories (Pakistan) in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Abbott Laboratories (Pakistan)'s value of 21.45% is 72.4% above this benchmark. Historically, Abbott Laboratories (Pakistan)'s own EBITDA Margin % has ranged from 7.56 to 26.20 over the past decade. While the company's 10-year median is 18.81 vs. the industry median of 12.44, Abbott Laboratories (Pakistan) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories (Pakistan)'s current EBITDA Margin % of 21.45% is 72.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Abbott Laboratories (Pakistan) and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories (Pakistan)'s current EBITDA Margin % is 21.45%, which is 14% above median its own 10-year median of 18.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories (Pakistan) stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) (KAR:ABOT) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,001.38, compared to a current price of ₨966.44 — trading 3.5% below its estimated fair value. The current EBITDA Margin % is 21.45%, which is 14% above median its 10-year median of 18.81 and 72.4% above the Drug Manufacturers industry median of 12.44. Abbott Laboratories (Pakistan)'s overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Abbott Laboratories (Pakistan) (KAR:ABOT), the current EBITDA Margin % is 21.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (Pakistan) (KAR:ABOT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) stock appears to be undervalued.
The current stock price of ₨966.44 is trading 3.5% below its estimated GF Value™ of ₨1,001.38.
GuruFocus considers Abbott Laboratories (Pakistan) to be Fairly Valued.
Key valuation signals for KAR:ABOT:
EBITDA Margin %: 21.45% (14% above median its 10-year median of 18.81)
GF Value™: ₨1,001.38 vs. price of ₨966.44 (3.5% below fair value)
Industry Position: 72.4% above the Drug Manufacturers median (#283 of 955)
No single metric tells the full story. See the KAR:ABOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott Laboratories (Pakistan) Business Description
Abbott Laboratories (Pakistan) Ltd manufactures, imports, and markets research-based pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. Its operating segments are Pharmaceutical, Nutritional, Diagnostics, and Others. It generates maximum revenue from the Pharmaceutical segment. Geographically, it derives the majority of its revenue from Pakistan and has a presence in Afghanistan, Sri Lanka, Bangladesh, and Switzerland. The company's Brands include Duphaston, Brufen, Surbex Z, Arinac, Glucerna, Pediasure, and Ensure.
77GF Score
Get the complete analysis for KAR:ABOT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:ABOT has been successfully added to your 
